Back to Search
Start Over
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
- Source :
- Annals of hematology. 99(5)
- Publication Year :
- 2019
-
Abstract
- Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an important component of therapeutic decision-making. This multi-centric, retrospective, observational study conducted by the treating physicians evaluated the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in 155 patients who received ixazomib via early access programs in Greece, the UK, and the Czech Republic. Median age was 68 years; 17% had an Eastern Cooperative Oncology Group performance status ≥ 2; median number of prior therapies was 1 (range 1–7); 91%, 47%, and 17% had received prior bortezomib, thalidomide, and lenalidomide, respectively. Median duration of exposure to ixazomib was 9.6 months. Overall response rate was 74%, including 35% very good partial response or better (16% complete response). Median progression-free survival (PFS) was 27.6 months (27.6 and 19.9 months in patients with 1 or > 1 prior lines, respectively). IRd treatment for ≥ 6 months was associated with longer PFS (hazard ratio 0.06). Fourteen patients (9%) discontinued IRd due to adverse events/toxicity in the absence of disease progression. Peripheral neuropathy was reported in 35% of patients (3% grades 3–4). These findings support the results of the phase III TOURMALINE-MM1 trial in a broader real-world RRMM population.
- Subjects :
- Oncology
Adult
Boron Compounds
Male
medicine.medical_specialty
Population
Glycine
Dexamethasone
Disease-Free Survival
Ixazomib
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Recurrence
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
education
Adverse effect
Lenalidomide
Multiple myeloma
Aged
Aged, 80 and over
education.field_of_study
Bortezomib
business.industry
Hazard ratio
Hematology
General Medicine
Middle Aged
medicine.disease
Thalidomide
Survival Rate
chemistry
030220 oncology & carcinogenesis
Female
business
Multiple Myeloma
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 14320584
- Volume :
- 99
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Annals of hematology
- Accession number :
- edsair.doi.dedup.....9c725aaf35ba02383cb2614fcc6b8770